NCT02478164

Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma

Phase II Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 17 (actual)
• Sponsor: Dana-Farber Cancer Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This research study is studying a chemotherapy as a possible treatment for recurrent glioblastoma that has not responded to bevacizumab. The name of the study drug involved in this study is Ponatinib.

Detailed description

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied. The FDA (the U.S. Food and Drug Administration) has not approved Ponatinib for your specific disease but it has been approved for other uses. Ponatinib is a drug that may stop cancer cells from growing by affecting different kinds of proteins in cancer cells. Glioblastoma cells can be driven by mutated forms of a protein called c-kit (KIT) which are present in glioblastoma cells. Laboratory studies suggest that ponatinib has activity against mutated forms of (KIT) which is important in glioblastoma and therefore suggests that ponatinib may help to control the growth of glioblastoma. In this research study the study team is looking to see if ponatinib is safe and is able to control the growth of glioblastoma in people who have not responded to treatment with bevacizumab.

Conditions

• Glioblastoma

Interventions

Type	Name	Description
DRUG	Ponatinib

Timeline

• Start date: 2015-07-13
• Primary completion: 2017-07-08
• Completion: 2018-05-09
• First posted: 2015-06-23
• Last updated: 2018-07-24
• Results posted: 2018-04-02

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study